<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286688</url>
  </required_header>
  <id_info>
    <org_study_id>01361</org_study_id>
    <nct_id>NCT01286688</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of terbinafine
      hydrochloride 250 mg tablets versus Lamisil® 250 mg tablets administered as 1 x 250 mg tablet
      under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, 2-way crossover, bioequivalence study of Terbinafine hydrochloride 250 mg tablets
      and Lamisil® 250 mg Tablets administered as 1 x 250 mg tablet in healthy subjects under
      fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">March 2002</completion_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study based on Cmax parameter</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Terbinafine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamisil® 250 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamisil® 250 mg Tablets of Novartis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine Hydrochloride Tablets, 250 mg</intervention_name>
    <description>Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.</description>
    <arm_group_label>Terbinafine Hydrochloride</arm_group_label>
    <arm_group_label>Lamisil® 250 mg Tablets</arm_group_label>
    <other_name>Lamisil® 250 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects enrolled in this study will be members of the community at large. The
             recruitment advertisements may be done using different media (e.g. radio, newspaper,
             Anapharm Web site, Anapharm volunteers' data base). ---Subjects must meet all of the
             following criteria in order to be included in the study:

          -  Subjects will be females and/or males, smokers and/or non-smokers, 18 years of age and
             older.

        Exclusion Criteria:

        Subjects to whom any of the following applies will be excluded from the study:

          -  Clinically significant illnesses within 4 weeks of the administration of study
             medication.

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the medical sub-investigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive urine drug screen at screening.

          -  Positive testing for hepatitis B, hepatitis C or HIV at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or
             over 90 mm Hg; or heart rate less than 50 bpm) at screening.

        Subjects with BMI ≥ 30.0.

          -  History of significant alcohol abuse within six months of the screening visit or any
             indication of the regular use of more than two units of alcohol per day (1 Unit = 150
             mL of wine or 360 mL of beer or 45 mL of alcohol 40%).

          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)
             within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine
             (PCP) and crack) within 1 year of the screening visit.

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             medical sub-investigator, contraindicates the subjects participation in this study.

          -  History of allergic reactions to terbinafine hydrochloride or other related drugs
             (e.g.naftifine).

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids,
             rifampin/rifabutin;examples of inhibitors: antidepressants, cimetidine, diltiazem,
             erythromycin,ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine), use of
             an investigational drug or participation in an investigational study within 30 days
             prior to administration of the study medication.

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products (including natural products, vitamins, garlic
             as supplement)within 7 days prior to administration of study medication, except for
             topical products without systemic absorption or oral contraceptives.

          -  Subjects who have a depot injection or an implant of any drug (except for depot
             injection or implant used as method of contraception) 3 months prior to administration
             of study medication.

          -  Subjects with a history of any previous liver disease.

        Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to
        administration of the study medication as follow:

          -  less than 300 mL of whole blood within 30 days or

          -  300 mL to 500 mL of whole blood within 45 days or

          -  more than 500 mL of whole blood within 56 days. •Smoking more than 25 cigarettes per
             day.

        Additional exclusion criteria for females only:

          -  Breast-feeding subjects.

          -  Positive urine pregnancy test at screening (performed on all females).

          -  Female subjects of childbearing potential who have had unprotected sexual intercourse
             with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy
             for at least 6 months) within 14 days prior to study drug administration. The
             acceptable methods of contraception are:

               -  Condom + spermicide

               -  Diaphragm + spermicide

               -  Intrauterine contraceptive device (placed at least 4 weeks prior to study drug
                  administration)

               -  oral contraceptives (starting at least 4 weeks prior to study drug
                  administration)

               -  Implant (e.g. Norplant®) (starting at least 4 weeks prior to study drug
                  administration)

               -  Depot injection of a progestogen drug (e.g. Depo-Provera®) (starting at least 4
                  weeks prior to study drug administration)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bicrell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Quebec</city>
        <zip>GIV 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ramakrishna Bangaru/Assistant Manager</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>crossover</keyword>
  <keyword>Terbinafine hydrochloride</keyword>
  <keyword>Fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

